【October 31 2016, Hong Kong】On 29 October 2016, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196.SH, 02196.HK), announced its financial results for the first three quarters ended 30 September 2016 in its latest A-share announcement, which generally maintained the growth momentum in the first half year.

In the first three quarters of 2016, Fosun Pharma recorded an operating revenue of RMB10.638 billion, representing an increase of 17.24% year on year; net profit attributable to equity holders of the Company was RMB2.177 billion, representing an increase of 15.12% year on year; net profit attributable to equity holders of the Company after deduction of non-recurring profit or loss was RMB1.661 billion, representing an increase of 26.92% year on year.

In the first three quarters of 2016, all the business of the Company maintained overall steady growth, and showed R&D innovative achievements, achieving fruitful results in the R&D of monoclonal antibody products. According to the Company announcement: innovative biobetter for monoclonal antibodies, which is called HLX07, of its holding subsidiary, Shanghai Henlius, had obtained approvals of clinical trials in three places, namely Mainland China, Taiwan and the U.S.. Another biosimilar for the treatment of breast cancer, which is called HER2 humanized monoclonal antibody, had also completed phase I of clinical trial and will commence phase III of clinical trial in the near future.

Besides, as announced earlier by the Company, the resolution of the acquisition of approximately 86.08% equity interest in Gland Pharma through its subsidiaries for no more than US$1,261.37 million was considered and approved at the extraordinary general meeting of the Company at the end of September. On the other hand, the resolutions of the listing of Sisram and Shanghai Henlius were also considered and approved by the Company and are pending the approvals from the competent authorities.

Fosun Pharma indicated that, it will continue to adhere to its strategies of “organic growth, external expansion and integrated development”. Fosun Pharma will seize the development opportunities of healthcare services to strengthen its investment and management in the healthcare services segment so as to further enhance its core competence. At the same time, it will step up its efforts to acquire and integrate with domestic and overseas quality pharmaceutical manufacturing companies so as to push forward the implementation of internationalization.

About Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading healthcare Group in the PRC. Fosun Pharma strategically covers important segments of the healthcare industry value-chain, including pharmaceutical manufacturing and R&D, healthcare services, medical diagnosis, medical devices manufacturing and agent, as well as pharmaceutical distribution and retail, making contribution to improving people’s health. Fosun Pharma maintains a National Recognized Enterprise Technology Centre and a highly capable international R&D team, focusing on innovation and research of therapeutic areas including cardiovascular system, central nervous system, blood system, metabolism and alimentary system, anti-infection and anti-tumor. With its commitment to innovation for good health and creating a better future, Fosun Pharma will continue insisting on the strategic development approach of “organic growth , external expansion and integrated development”, striving to be one of the leading enterprises in the global healthcare market.